Citation
Lu, Yue, et al. "[HLA- Haploidentical Donor Hematopoietic Transplantation for Severe Aplastic Anemia Achieved Comparable Outcomes With HLA- Unrelated Donor Transplantation]." Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, vol. 37, no. 1, 2016, pp. 35-8.
Lu Y, Wu T, Cao X, et al. [HLA- haploidentical donor hematopoietic transplantation for severe aplastic anemia achieved comparable outcomes with HLA- unrelated donor transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2016;37(1):35-8.
Lu, Y., Wu, T., Cao, X., Zhao, Y., Liu, D., Sun, R., Xiong, M., Wei, Z., Zhang, J., Zhou, J., & Lu, D. (2016). [HLA- haploidentical donor hematopoietic transplantation for severe aplastic anemia achieved comparable outcomes with HLA- unrelated donor transplantation]. Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi, 37(1), 35-8. https://doi.org/10.3760/cma.j.issn.0253-2727.2016.01.007
Lu Y, et al. [HLA- Haploidentical Donor Hematopoietic Transplantation for Severe Aplastic Anemia Achieved Comparable Outcomes With HLA- Unrelated Donor Transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2016;37(1):35-8. PubMed PMID: 26876251.
TY - JOUR
T1 - [HLA- haploidentical donor hematopoietic transplantation for severe aplastic anemia achieved comparable outcomes with HLA- unrelated donor transplantation].
AU - Lu,Yue,
AU - Wu,Tong,
AU - Cao,Xingyu,
AU - Zhao,Yanli,
AU - Liu,Deyan,
AU - Sun,Ruijuan,
AU - Xiong,Min,
AU - Wei,Zhijie,
AU - Zhang,Jianping,
AU - Zhou,Jiarui,
AU - Lu,Daopei,
PY - 2016/2/16/entrez
PY - 2016/2/16/pubmed
PY - 2016/7/7/medline
SP - 35
EP - 8
JF - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JO - Zhonghua Xue Ye Xue Za Zhi
VL - 37
IS - 1
N2 - OBJECTIVE: To evaluate the efficacy of HLA- haploidentical donor hematopoietic transplantation (Haplo- HSCT)for severe aplastic anemia (SAA)by compared with the same period of unrelated donor transplantation (UD- HSCT). METHODS: Of a cohort of 50 SAA patients between September 2012 and July 2014, 26 patients underwent UD- HSCT and 24 patients Haplo- HSCT. RESULTS: OS rate was 91.3% with a median follow-up of 9 (2-26)months. According to transplant type, there was no significant difference between UD- and Haplo-HSCT (96.1%vs 86.0%,P=0.30). 3 of 50 (6%)patients had primary engraft failure. Haplo- HSCT developed higher significantly incidence of Ⅱ- Ⅳ aGVHD (37.5%vs 3.83%,P=0.003)and cGVHD (37.5%vs 15.3%,P=0.030)than UD-HSCT. Haplo-HSCT also had significantly higher incidences of CMV viremia (78.2%vs 46.1%,P=0.005)and EBV viremia (43.1%vs 16.0%,P=0.040), respectively than UD-HSCT. But the incidences of hemorrhagic cystitis were similar between two transplant types (39.1%vs 23.0%,P=0.120). CONCLUSION: This study showed favorable outcome of Haplo-HSCT for SAA, which was comparable with UD-HSCT.
SN - 0253-2727
UR - https://www.unboundmedicine.com/medline/citation/26876251/[HLA__haploidentical_donor_hematopoietic_transplantation_for_severe_aplastic_anemia_achieved_comparable_outcomes_with_HLA__unrelated_donor_transplantation]_
L2 - http://journal.yiigle.com/LinkIn.do?linkin_type=pubmed&issn=0253-2727&year=2016&vol=37&issue=1&fpage=35
DB - PRIME
DP - Unbound Medicine
ER -